(ENTA) Enanta Pharmaceuticals - Overview

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US29251M1062

Stock: Antiviral, Hepatitis, Protease, Immunology, Pipeline

Total Rating 42

Risk 36

Buy Signal -0.41

Biotechnology » Biotechnology
Age: 12.9y

Market Cap: 374m
Avg Trading Vol: 2.70M USD

ATR: 5.30%
Peers RS (IBD): 77.50

EPS (Earnings per Share)

EPS CAGR: 57.34%
EPS Trend: 73.4%

Last SUE: 2.60
Qual. Beats: 1

Revenue

Rev. CAGR: -14.86%
Rev. Trend: -76.5%

Last SUE: -0.35
Qual. Beats: 0

Risk 5d forecast
Volatility	66.9%
Relative Tail Risk	-9.93%

Reward TTM
Sharpe Ratio	1.27
Alpha	151.71

Character TTM
Beta	0.924
Beta Downside	1.229

Drawdowns 3y
Max DD	91.97%
CAGR/Max DD	-0.40

Description: ENTA Enanta Pharmaceuticals January 02, 2026

Enanta Pharmaceuticals (NASDAQ: ENTA) is a U.S. biotech focused on small-molecule antivirals and immunology agents. Its pipeline includes EDP-514 (Phase 1b for chronic hepatitis B), zelicapavir and EDP-323 (Phase II for respiratory syncytial virus), EDP-235 (Phase II for human coronaviruses), and the marketed HCV protease inhibitor glecaprevir, which is commercialized under a development and license partnership with Abbott Laboratories.

Key financial metrics (as of the latest 10-Q) show a cash runway of roughly $200 million, a quarterly burn rate of about $30 million, and a market-cap near $1.1 billion, giving the company roughly 6–7 months of liquidity without additional financing.

Sector drivers that could amplify Enanta’s upside include the persistent global demand for curative hepatitis B and C therapies, the growing market for RSV treatments in pediatric and elderly populations (projected CAGR ≈ 12% through 2030), and the broader biotech funding environment, which has seen a 15% YoY increase in venture capital allocations to antiviral platforms.

For a deeper quantitative view, you may want to explore Enanta’s profile on ValueRay.

Piotroski VR‑10 (Strict, 0-10) 0.5

Net Income: -81.9m TTM > 0 and > 6% of Revenue
FCF/TA: -0.11 > 0.02 and ΔFCF/TA 14.22 > 1.0
NWC/Revenue: 238.5% < 20% (prev 358.3%; Δ -119.8% < -1%)
CFO/TA -0.07 > 3% & CFO -19.3m > Net Income -81.9m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 4.21 > 1.5 & < 3
Outstanding Shares: last quarter (21.4m) vs 12m ago 0.90% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 19.87% > 50% (prev 17.96%; Δ 1.92% > 0%)
Interest Coverage Ratio: -7.76 > 6 (EBITDA TTM -72.6m / Interest Expense TTM 7.68m)

Altman Z'' -4.25

A: 0.55 (Total Current Assets 204.3m - Total Current Liabilities 48.6m) / Total Assets 280.7m
B: -1.44 (Retained Earnings -404.9m / Total Assets 280.7m)
C: -0.18 (EBIT TTM -59.6m / Avg Total Assets 328.7m)
D: -1.88 (Book Value of Equity -405.1m / Total Liabilities 216.0m)
Altman-Z'' Score: -4.25 = D

Beneish M -3.75

DSRI: 0.18 (Receivables 6.88m/38.6m, Revenue 65.3m/67.6m)
GMI: 1.00 (GM 96.80% / 96.55%)
AQI: 1.34 (AQ_t 0.01 / AQ_t-1 0.01)
SGI: 0.97 (Revenue 65.3m / 67.6m)
TATA: -0.22 (NI -81.9m - CFO -19.3m) / TA 280.7m)
Beneish M-Score: -3.75 (Cap -4..+1) = AAA

What is the price of ENTA shares?

As of February 09, 2026, the stock is trading at USD 13.51 with a total of 164,022 shares traded.
Over the past week, the price has changed by +4.73%, over one month by -0.52%, over three months by +25.09% and over the past year by +172.38%.

Is ENTA a buy, sell or hold?

Enanta Pharmaceuticals has received a consensus analysts rating of 3.67. Therefor, it is recommend to hold ENTA.

StrongBuy: 2
Buy: 1
Hold: 2
Sell: 1
StrongSell: 0

What are the forecasts/targets for the ENTA price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	19.1	41.6%
Analysts Target Price	19.1	41.6%
ValueRay Target Price	11.3	-16.2%

ENTA Fundamental Data Overview February 02, 2026

P/S = 5.7305
P/B = 5.7842
Revenue TTM = 65.3m USD
EBIT TTM = -59.6m USD
EBITDA TTM = -72.6m USD
Long Term Debt = 57.9m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 33.9m USD (from shortTermDebt, last quarter)
Debt = 201.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 168.8m USD (from netDebt column, last quarter)
Enterprise Value = 386.5m USD (374.3m + Debt 201.1m - CCE 188.9m)
Interest Coverage Ratio = -7.76 (Ebit TTM -59.6m / Interest Expense TTM 7.68m)
EV/FCF = -12.02x (Enterprise Value 386.5m / FCF TTM -32.2m)
FCF Yield = -8.32% (FCF TTM -32.2m / Enterprise Value 386.5m)
FCF Margin = -49.24% (FCF TTM -32.2m / Revenue TTM 65.3m)
Net Margin = -125.4% (Net Income TTM -81.9m / Revenue TTM 65.3m)
Gross Margin = unknown ((Revenue TTM 65.3m - Cost of Revenue TTM 2.09m) / Revenue TTM)
Tobins Q-Ratio = 1.38 (Enterprise Value 386.5m / Total Assets 280.7m)
Interest Expense / Debt = 1.19% (Interest Expense 2.39m / Debt 201.1m)
Taxrate = 21.0% (US default 21%)
NOPAT = -47.1m (EBIT -59.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.21 (Total Current Assets 204.3m / Total Current Liabilities 48.6m)
Debt / Equity = 3.11 (Debt 201.1m / totalStockholderEquity, last quarter 64.7m)
Debt / EBITDA = -2.33 (negative EBITDA) (Net Debt 168.8m / EBITDA -72.6m)
Debt / FCF = -5.25 (negative FCF - burning cash) (Net Debt 168.8m / FCF TTM -32.2m)
Total Stockholder Equity = 87.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -24.91% (Net Income -81.9m / Total Assets 280.7m)
RoE = -93.76% (Net Income TTM -81.9m / Total Stockholder Equity 87.3m)
RoCE = -41.03% (EBIT -59.6m / Capital Employed (Equity 87.3m + L.T.Debt 57.9m))
RoIC = -53.90% (negative operating profit) (NOPAT -47.1m / Invested Capital 87.3m)
WACC = 6.39% (E(374.3m)/V(575.4m) * Re(9.32%) + D(201.1m)/V(575.4m) * Rd(1.19%) * (1-Tc(0.21)))
Discount Rate = 9.32% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.69%
Fair Price DCF = unknown (Cash Flow -32.2m)
EPS Correlation: 73.42 | EPS CAGR: 57.34% | SUE: 2.60 | # QB: 1
Revenue Correlation: -76.52 | Revenue CAGR: -14.86% | SUE: -0.35 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.81 | Chg30d=-0.040 | Revisions Net=+0 | Analysts=5
EPS current Year (2026-09-30): EPS=-3.09 | Chg30d=-0.021 | Revisions Net=+0 | Growth EPS=+19.6% | Growth Revenue=-1.0%
EPS next Year (2027-09-30): EPS=-2.73 | Chg30d=-0.232 | Revisions Net=+0 | Growth EPS=+11.5% | Growth Revenue=+0.3%

Additional Sources for ENTA Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Fund Manager Positions: Dataroma | Stockcircle